SEARCH

SEARCH BY CITATION

References

  • 1
    American Sleep Disorders Association Atlas Task Force. EEG arousals: scoring rules and examples. Sleep, 1992, 15: 173 184.
  • 2
    American Sleep Disorders Association Atlas Task Force. Recording and scoring leg movements. Sleep, 1993, 16: 749 759.
  • 3
    Baker, T., Guilleminault, C., Nino-Murcia, G., Dement, W. Comparative polysomnographic study of narcolepsy and idiopathic central nervous system hypersomnia. Sleep, 1986, 9: 232 242.
  • 4
    Benbadis, S. R., Perry, M., Wolgamuth, B. R., Turnbull, J., Mendelson, W. B. Mean versus median for the multiple sleep latency test. Sleep, 1995, 18: 342 345.
  • 5
    Boivin, D. B. & Montplaisir, J. The effects of l-dopa on excessive daytime sleepiness in narcolepsy. Neurology, 1991, 41: 1267 1269.
  • 6
    Boivin, D. B., Montplaisir, J., Poirer, G. The effects of l-dopa on periodic leg movements and sleep organization in narcolepsy. Clin. Neuropharmacol., 1989, 12: 339 345.
  • 7
    Borbely, A. A., Akerstedt, T., Benoit, O., Holsboer, F., Oswald, I. Hypnotics and sleep physiology: a consensus report. Eur Arch. Psychiatry Clin. Neurosci., 1991, 241: 13 21.
  • 8
    Bornstein, S. K. Respiratory monitoring during sleep: polysomnography. In: C. Guilleminault (Eds) Sleep and Waking Disorders: Indications and Techniques. Addison-Wesley, Menlo Park, CA, 1982: 183–212.
  • 9
    Carskadon, M. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep, 1986, 9: 519 524.
  • 10
    Chervin, R. D. Sleepiness, fatigue, tiredness, and lack of energy in obstructive sleep apnea. Sleep Res. Online, in press.
  • 11
    Daley, J., Turner, R., Bliwise, D., Rye, D. Nocturnal sleep and daytime alertness in the MPTP-treated primate. Sleep, 1999, 22 (suppl.): S218 S219.
  • 12
    Dihenia, B., Rye, D., Bliwise, D. Daytime alertness in Parkinson’s disease. Sleep Res., 1997, 26: 550550.
  • 13
    Factor, S., McAlarney, T., Sanchez-Ramos, J., Weiner, W. Sleep disorders and sleep effect in Parkinson’s disease. Mov Disord., 1990, 5: 280 285.
  • 14
    Frucht, S., Rogers, J., Greene, P., Gordon, M., Fahn, S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology, 1999, 52: 1908 1910.
  • 15
    Halliday, G. M., Li, Y. W., Blumbergs, P. C., Joh, T. H., Cotton, R. G. H., Howe, P. R. C., Blessing, W. W., Geffen, L. B. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson’s disease. Ann. Neurol., 1990, 27: 373 385.
  • 16
    Hoehn, M. M. & Yahr, M. D. Parkinsonism: onset, progression, and mortality. Neurology, 1967, 17: 427 442.
  • 17
    Hublin, C., Partinen, M., Heinonen, E. H., Puukka, P., Salmi, T. Selegiline in the treatment of narcolepsy. Neurology, 1994, 44: 2095 2101.
  • 18
    Jellinger, K. Pathology of Parkinson’s disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol., 1991, 14: 153 197.
  • 19
    Karoum, F., Chuang, L. W., Eisler, T., Calne, D. B., Liebowitz, M. R., Quitkin, F. M., Klein, D. F., Wyatt, R. J. Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl’s therapeutic benefit: a biochemical assessment. Neurology, 1982, 32: 503 509.
  • 20
    Langston, J. W. & Forno, L. S. The hypothalamus in Parkinson’s disease. Ann. Neurol., 1978, 3: 129 133.
  • 21
    Lees, A. J., Blackburn, N. A., Campbell, V. L. The nighttime problems of Parkinson’s Disease. Clin. Neuropharmacol., 1988, 11: 512 519.
  • 22
    Mayer, G., Ewert Meier, K., Hephata, K. Selegiline hydrochloride treatment in narcolepsy. a double-blind, placebo-controlled study. Clin. Neuropharmacol., 1995, 18: 306 319.
  • 23
    Miller, E. & Nieburg, H. A. Amphetamines, valuable adjunct in treatment of Parkinsonism. N Y State J. Med., 1973, 73: 2657 2661.
  • 24
    Nishino, S. & Mignot, E. Pharmacological aspects of human and canine narcolepsy. Prog. Neurobiol., 1997, 52: 27 78.
  • 25
    Olanow, C. W., Schapira, A. H. V., Roth, T. Falling asleep at the wheel: motor vehicle mishaps in people taking pramipexole and ropinirole (letter). Neurology, 2000, 54: 274 277
  • 26
    Parkes, J. D., Tarsy, D., Marsden, C. D., Bovill, K. T., Phipps, J. A., Rose, P., Asselman, P. Amphetamines in the treatment of Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry, 1975, 38: 232 237.
  • 27
    Rechtschaffen, A. & Kales, A., (Eds) A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. US Government Printing Office, Washington, 1968.
  • 28
    Reynolds, C. F.III, Jennings, J. R., Hoch, C. C., Monk, T. H., Berman, S. R., Hall, F. T., Matizzie, J. V., Buysse, D. J., Kupfer, D. J. Daytime sleepiness in the healthy ‘old old’; a comparison with young adults. JAGS, 1991, 39: 957 962.
  • 29
    Reynolds, C. F. III, Kupfer, D. J., Taska, L. S., Hoch, C. C., Spiker, D. G., Sewitch, D. E., Zimmer, B., Marin, R. S., Nelson, J. P., Martin, D., Morycz, R. EEG sleep in elderly depressed, demented, and healthy subjects. Biol. Psychiatry, 1985, 20: 431 442.
  • 30
    Rye, D. & Bliwise, D. Movement disorders specific to sleep and the nocturnal manifestations of waking movement disorders. In: R. Watts and W. Koller (Eds) Movement Disorders: Neurologic Principles and Practice. McGraw-Hill, New York, 1997: 687–713.
  • 31
    Rye, D., Johnston, L., Watts, R., Bliwise, D. Juvenile Parkinson’s disease with REM behavior disorder, sleepiness and daytime REM-onsets. Neurology, 1999, 53: 1868 1870.
  • 32
    Sacks, O. Awakenings. E. P. Dutton, New York, 1973.
  • 33
    Schenck, C. & Mahowald, M. Motor dyscontrol in narcolepsy: rapid eye movement (REM) sleep without atonia and REM sleep behavior disorder. Ann. Neurol., 1992, 32: 3 10.
  • 34
    Scheibel, A. B. Structural and functional changes in the aging brain. In: J. E. Birren and K. W. Schaie (Eds) Handbook of the Psychology of Aging. Academic, San Diego, 1996 (fourth edition): 105–128.
  • 35
    Van Hilten, J. J., Weggeman, M., Van Der Velde, E. A., Kerkhof, G. A., Van Dijk, J. G., Roos, R. A. C. Sleep, excessive daytime sleepiness and fatigue in Parkinson’s disease. J. Neurol. Transm., 1993, 5: 235 244.
  • 36
    Wauquier, A., Clincke, G., Van Den Broek, W., De Prins, E. Active and permissive roles of dopamine in sleep-wakefulness regulation. In: A. Wauquier, J. M. Gaillard, J. M. Monti and M. Radulovacki (Eds) Sleep: Neurotransmitters and Neuromodulators. Raven Press, New York, 1985: 107–120.
  • 37
    Williams, M. L., Irbe, D., Ansari, F. P., Rye, D. B., Bliwise, D. L. Stage scoring reliability for nocturnal polysomnography in patients with Parkinson’s Disease. Sleep, 1998, 21 (suppl.): 171171.
  • 38
    Zweig, R. M., Cardillo, J. E., Cohen, M., Giere, S., Hedreen, J. C. The locus ceruleus and dementia in Parkinson’s disease. Neurology, 1993, 43: 986 991.